Banco Bilbao Vizcaya Argentaria S.A. Has $4.50 Million Stock Holdings in Illumina, Inc. $ILMN

Banco Bilbao Vizcaya Argentaria S.A. lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 21.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,159 shares of the life sciences company’s stock after selling 13,001 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Illumina were worth $4,499,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ILMN. Corvex Management LP lifted its stake in Illumina by 125.2% in the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after buying an additional 2,129,449 shares during the period. AQR Capital Management LLC increased its stake in shares of Illumina by 361.7% in the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after acquiring an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after acquiring an additional 1,152,048 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock worth $155,537,000 after acquiring an additional 667,978 shares during the last quarter. Finally, PGGM Investments grew its holdings in Illumina by 115.1% during the second quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company’s stock valued at $109,665,000 after purchasing an additional 614,973 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 0.6%

NASDAQ:ILMN opened at $120.67 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market cap of $18.44 billion, a PE ratio of 15.27, a PEG ratio of 2.34 and a beta of 1.42. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $153.06. The stock has a 50-day simple moving average of $102.84 and a 200 day simple moving average of $95.99.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other Illumina news, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on ILMN shares. Morgan Stanley upped their target price on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a research report on Tuesday, September 2nd. UBS Group raised their price objective on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.